1. Willingness to participate in the clinical study.
2. Age ≥ 18 years at the time of signing the Informed Consent Form (ICF).
3. Newly diagnosed ENKTL confirmed by histopathology at the study center.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
5. At least one evaluable or measurable lesion
6. Ann Arbor stage I-II disease.
7. PINK-E score ≥ 1.
8. Adequate organ and bone marrow function, with no severe hematopoietic dysfunction or abnormalities in cardiac, pulmonary, hepatic, renal, or thyroid function, and no immunodeficiency.
You may not be if
1. Aggressive natural killer cell leukemia.
2. Presence of hemophagocytic syndrome.
3. Primary central nervous system (CNS) lymphoma or secondary CNS involvement.
4. Patients with a known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome (AIDS).
5. Patients with active chronic hepatitis B or active hepatitis C.
Clareo Health | Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
